Switching statins leads to lower therapy persistence
Patients who switch statins have lower persistence to therapy compared to those who don't switch, found Gary J. Tereso, PharmD, director of pharmacy services at Health New England, Springfield, Mass.
Key Points
Patients who switch statins have lower persistence to therapy compared to those who don't switch, found Gary J. Tereso, PharmD, director of pharmacy services at Health New England, Springfield, Mass.
The poster "Evaluation of adherence and persistence in members who switched statins" was presented at the 45th midyear meeting of the American Society of Health-System Pharmacists.
A retrospective review of patients who were prescribed a statin was conducted. Patients were followed for 360 days from the date of their index claim.
A switch was defined as any prescription for a non-index statin during follow-up, with the exception of a generic equivalent switched for the index statin.
Some 129 of the 1,331 who were new users of statins switched; the most common switch was from simvastatin to atorvastatin (42 patients; 33.6%).
Of the 7,556 who were previously prescribed a statin, 767 switched products; 24.5% who were on atorvastatin switched to simvastatin; 8.7% who were prescribed lovastatin switched to simvastatin; 13.8% who were on simvastatin switched to atorvastatin; and 7.2% who were on simvastatin/ezetimibe switched to simvastatin.
Among the switchers, 38.2% of the newly prescribed group and 44.5% of the previous statin users had a proportion of days covered (the number of days the medication was available divided by the total number of days of the follow-up period) of at least 80%, compared to 41.6% and 56.2%, respectively, of those who didn't switch.
"Persistence at 1 year was significantly higher in members who did not switch therapy, and more members not switching had a high proportion of days covered compared to members who switched statin," according to Dr Tereso.
Persistence at 360 days was 16.3% (new users) and 26.3% (previous users) compared to 25.0% (new users) and 38.5% (previous users) in the nonswitchers.
"The results demonstrate the potential unintended consequences of switching therapy on medication adherence and persistence, and warrant further review," said Dr Tereso.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
